Advertisement
Grab your lab coat. Let's get started
Welcome!
Welcome!
Create an account below to get 6 C&EN articles per month, receive newsletters and more - all free.
It seems this is your first time logging in online. Please enter the following information to continue.
As an ACS member you automatically get access to this site. All we need is few more details to create your reading experience.
Not you? Sign in with a different account.
Not you? Sign in with a different account.
ERROR 1
ERROR 1
ERROR 2
ERROR 2
ERROR 2
ERROR 2
ERROR 2
Password and Confirm password must match.
If you have an ACS member number, please enter it here so we can link this account to your membership. (optional)
ERROR 2
ACS values your privacy. By submitting your information, you are gaining access to C&EN and subscribing to our weekly newsletter. We use the information you provide to make your reading experience better, and we will never sell your data to third party members.
Pharmaceuticals
BMS Gets Rights To Promedior Drug
by Ann M. Thayer
September 7, 2015
| A version of this story appeared in
Volume 93, Issue 35
Bristol-Myers Squibb could pay up to $1.25 billion to acquire Lexington, Mass.-based Promedior and its lead product candidate, PRM-151, a recombinant form of human pentraxin-2 protein. Fast-tracked and given orphan drug designation, PRM-151 is in development for the treatment of idiopathic pulmonary fibrosis and myelofibrosis. BMS will pay $150 million in cash for the right to acquire Promedior and to support Phase II clinical development of PRM-151. BMS could pay more than $1 billion more to exercise its rights and for clinical and regulatory milestone payments.
The power is now in your (nitrile gloved) hands
Sign up for a free account to get more articles. Or choose the ACS option that’s right for you.
Already have an ACS ID? Log in
Join the conversation
Contact the reporter
Submit a Letter to the Editor for publication
Engage with us on Twitter